Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the colon~  * Metastatic or recurrent disease~ * Redocumentation of tumor histology or cytology prior to protocol therapy is not required if documented tumor was confirmed prior to initial therapy~* Measurable disease~  * Lesion of ≥ 1 cm in longest diameter that can be repetitively assessed by radiographic measurement or any lesion of ≥ 2 cm in longest diameter that can be repetitively assessed by physical examination~ * Positive bone scans, osteoblastic or osteolytic bone lesions, pleural effusions, and positive bone marrow biopsies are not considered measurable or evaluable lesions~* Metastatic disease to the brain allowed if emergent radiotherapy for symptomatic CNS disease is not required~* Must have received at least one prior chemotherapy regimen (with or without radiotherapy)~  * One of the prior regimens must include irinotecan hydrochloride, fluorouracil, and leucovorin calcium or irinotecan hydrochloride and other fluoropyrimidine~ * Previous therapy with C-225 and/or bevacizumab is allowed~* .~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Granulocyte count ≥1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Creatinine ≤ 2.0 mg/dL~* Bilirubin \< 1.5 mg/dL~* SGOT ≤ 2 times upper limit of normal (ULN)~* Alkaline phosphatase \< 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No serious medical or psychiatric illness that would render chemotherapy unsafe~* No concurrent clinically evident malignancy except inactive nonmelanoma skin cancer, low-grade low-stage bladder carcinoma followed off therapy, or lobular neoplasia of the breast~* No clinical AIDS or known positive HIV serology~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* No investigational agent for at least 30 days prior to study entry~* No chemotherapy within the past 3 weeks~* No radiotherapy for palliation within the past 2 weeks prior to study entry~* No prior oxaliplatin or gemcitabine hydrochloride~* No concurrent participation in another clinical trial~* No other concurrent anticancer therapy including chemotherapy, radiotherapy, hormonal therapy, or immunotherapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).